A new era in the treatment of Parkinson's disease has begun. Eldepryl is the new, selective inhibitor of the enzyme responsible for dopamine breakdown in the brain. Used in conjunction with L-dopa or L-dopa/decarboxylase inhibitor combinations, Eldepryl provides the next vital step in treatment of all stages of Parkinson's disease – dopamine conservation.

The patient benefits of Eldepryl are substantial – daily L-dopa intake can be immediately cut by 20% in most cases [1,2] reducing unwanted side-effects and extending the useful life of L-dopa. With a notable lack of adverse effects, Eldepryl significantly reduces akinesia, smoothes out "on-off" effects, and has been shown in a recent long-term study [3] to significantly prolong the evolution of the disease.

With Eldepryl, there is no complicated dosage regime to remember, simply one tablet daily, together with a 20% reduction of L-dopa on the first day of treatment, is usually all that is required.

PRESCRIBING INFORMATION

Presentation: White scored, uncoated tablets each containing 5 mg selegiline hydrochloride. Indications: ... indicated for the treatment of Parkinson's disease, or Parkinsonism, which is being treated with levodopa and a peripheral decarboxylase inhibitor. ... in conjunction with levodopa treatment in Parkinson's patients who, during chronic levodopa treatment, ... symptoms or other dyskinesias. ... in conjunction with established levodopa ... Eldepryl 5 mg, titrated in the morning ... severe e.g. on/off symptoms, and ... with 1 tablet Eldepryl daily, the dose of Eldepryl can be increased ... in the morning. **CONTRA-INDICATIONS, WARNINGS ETC.** Contra-indications: There are no known contra-indications for the use of Eldepryl in patients receiving levodopa therapy. Warnings: Because Eldepryl potentiates the effects of levodopa, the side effects of levodopa might be ... Side Effects. ... Category ... Date of Preparation: ...

ADD ELDEPRYL®

Selegiline hydrochloride

Whenever you prescribe L-dopa

Further information is available on request from Britannia Pharmaceuticals Limited, Hamilton House, 87-89 Bell Street, Reigate, Surrey RH2 7YZ.

Published by British Medical Association, Tavistock Square, London WC1H 9JR
and printed in England by Eyre & Spottiswoode Ltd, Thanet Press, Margate